The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos Acquisition by Novartis for up to $3.1 Billion
Feb 11, 2025•over 1 year ago
Contract Type
agreement
CambridgeBiotechnologyHealth CareTherapeutics
Description
Blackstone Life Sciences and Anthos Therapeutics, Inc. have announced an agreement with Novartis for the acquisition of Anthos for up to $3.1 billion. The agreement reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions, as well as Abelacimab’s potential to provide superior safety.
Company Information
Company
Anthos Therapeutics
Location
Cambridge, Massachusetts, United States
About
Anthos Therapeutics, Inc. (Anthos) is a clinical-stage company developing innovative therapies for cardiovascular diseases. The company was founded by Blackstone Life Sciences (BXLS) and is focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for high-risk cardiovascular patients.
Predictive Intelligence
Strategic
ML-powered predictions for Anthos Therapeutics's next move
CambridgeBiotechnologyHealth CareTherapeutics